ReviewBioMed research international2025
The Role of miR-138 in Cardiovascular Diseases.
Review in BioMed research international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of miR-138 in Cardiovascular Diseases.BioMed research international · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) represents the foremost cause of morbidity and mortality globally, posing a significant threat to human health. The regulatory mechanisms underlying CVD are still not fully elucidated. MicroRNA (miRNA), a class of noncoding short-chain RNA molecules, modulates individual genes or gene networks by binding to the complementary sequences of specific target genes, thereby influencing various biological processes including cell genesis, metabolism, proliferation, differentiation, and apoptosis. Among these, miR-138 plays a significant role in the onset and progression of CVDs. This article reviews the involvement of miR-138 in various cardiovascular conditions, including atherosclerosis (AS), myocardial ischemia-reperfusion injury (I/R), heart failure (HF), and pulmonary arterial hypertension (PAH), thereby offering novel insights for the prevention, diagnosis, and treatment of CVDs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.